RNIB: Eye health – Policy Statements

31 January 2019
Source: RNIB

Sight is precious and the sense people most fear losing. In the UK it is estimated that almost 2 million people are affected by sight loss and the number of people at risk of the main causes of blindness – cataract, glaucoma, wet age-related macular degeneration and diabetic retinopathy – is set to increase by up to 25 per cent

Read more RNIB: Eye health – Policy Statements

The Royal College of Ophthalmologists is delighted at landmark ruling in favour of the use of Avastin for wet AMD

21 September 2018
Source: Royal College of Ophthalmologists

The Royal College of Ophthalmologists (RCOphth) welcomes the High Court decision that has found in favour for the use of bevacizumab (Avastin) in the treatment of wet age related macular degeneration (wet AMD). Wet AMD is the biggest cause of vision loss in the UK and the hospital eye service is dealing with over 40,000 new diagnoses of wet AMD

Read more The Royal College of Ophthalmologists is delighted at landmark ruling in favour of the use of Avastin for wet AMD

BBC News: NHS to save ‘hundreds of millions’ in landmark (Avsatin) drug ruling

21 September 2018
Source: BBC News

A landmark ruling against two leading drug companies could save the NHS “hundreds of millions” a year. Novartis and Bayer were trying to stop NHS doctors from prescribing a cheaper treatment for a serious eye condition. Twelve NHS bodies in the north east of England were offering patients Avastin, a cheaper alternative to the licensed drug, Lucentis. Health bosses said

Read more BBC News: NHS to save ‘hundreds of millions’ in landmark (Avsatin) drug ruling

Guardian: Cheap blindness drug should be made widely available, says WHO

1 June 2016
Source: Guardian

World Health Organisation rejects expensive licensed drug Lucentis to be added to list for all countries in favour of much cheaper Avastin, not yet available in UK. All countries should make available a cheap, unlicensed drug to prevent blindness in older people – one in preference to the expensive licensed version promoted by pharmaceutical companies, a World Health Organisation committee

Read more Guardian: Cheap blindness drug should be made widely available, says WHO